Cargando…

Emerging Therapies and Future Directions in Targeting the Tumor Stroma and Immune System in the Treatment of Pancreatic Adenocarcinoma

Pancreatic adenocarcinoma is typically refractory to conventional treatments and associated with poor prognosis. While therapeutic advances over the past several years have improved patient outcomes, the observed benefits have been modest at best, highlighting the need for continued development of a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ahn, Daniel H., Ramanathan, Ramesh K., Bekaii-Saab, Tanios
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2018
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6025083/ https://www.ncbi.nlm.nih.gov/pubmed/29891787 http://dx.doi.org/10.3390/cancers10060193

Ejemplares similares

Update to “Homologous Recombination Repair Defect May Predict Treatment Response to Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors”
por: Zhu, Mojun, et al.
Publicado: (2022)

Targeting KRAS in pancreatic adenocarcinoma: Progress in demystifying the holy grail
por: Elhariri, Ahmed, et al.
Publicado: (2023)

Therapeutic Targeting Strategies of Cancer Stem Cells in Gastrointestinal Malignancies
por: Sonbol, Mohamad B., et al.
Publicado: (2019)

Identifying and targeting cancer stem cells in the treatment of gastric cancer
por: Bekaii‐Saab, Tanios, et al.
Publicado: (2017)

The Continued Promise and Many Disappointments of Oncolytic Virotherapy in Gastrointestinal Malignancies
por: Ahn, Daniel H., et al.
Publicado: (2017)

Response to Drs Von Hoff and Renschler
por: Ahn, Daniel H., et al.
Publicado: (2017)

Spotlight on bevacizumab in metastatic colorectal cancer: patient selection and perspectives
por: Bupathi, Manojkumar, et al.
Publicado: (2016)

New developments in the treatment of metastatic gastric cancer: focus on trastuzumab
por: Rose, Jeffrey S, et al.
Publicado: (2011)

CpG Island Methylation, Microsatellite Instability, and BRAF Mutations and Their Clinical Application in the Treatment of Colon Cancer
por: Wu, Christina, et al.
Publicado: (2012)

Maintenance Therapy in First-Line Gastric and Gastroesophageal Junction Adenocarcinoma: A Retrospective Analysis
por: Walden, Daniel, et al.
Publicado: (2021)

Emerging concepts in pancreatic cancer medicine: targeting the tumor stroma
por: Neesse, Albrecht, et al.
Publicado: (2013)

Immune features of the peritumoral stroma in pancreatic ductal adenocarcinoma
por: Ahmed, Azaz, et al.
Publicado: (2022)

Management of Venous Thromboembolism in Patients with Advanced Gastrointestinal Cancers: What Is the Role of Novel Oral Anticoagulants?
por: Martin, Ludmila Katherine, et al.
Publicado: (2012)

The tumor–stroma ratio and the immune microenvironment improve the prognostic prediction of pancreatic ductal adenocarcinoma
por: Lu, Mei, et al.
Publicado: (2023)

Frontline therapy for advanced hepatocellular carcinoma: an update
por: Akce, Mehmet, et al.
Publicado: (2022)

Pemigatinib for adults with previously treated, locally advanced or metastatic cholangiocarcinoma with FGFR2 fusions/rearrangements
por: Walden, Daniel, et al.
Publicado: (2022)

Whole-exome tumor sequencing study in biliary cancer patients with a response to MEK inhibitors
por: Ahn, Daniel H., et al.
Publicado: (2015)

Circulating Cell-Free Tumor DNA in Advanced Pancreatic Adenocarcinoma Identifies Patients With Worse Overall Survival
por: Botrus, Gehan, et al.
Publicado: (2022)

Tenascin C, Fibronectin, and Tumor-Stroma Ratio in Pancreatic Ductal Adenocarcinoma
por: Leppänen, Joni, et al.
Publicado: (2019)

Adjuvant therapy for pancreas cancer in an era of value based cancer care
por: Ahn, Daniel H., et al.
Publicado: (2015)

Suppression of Tumor Growth and Muscle Wasting in a Transgenic Mouse Model of Pancreatic Cancer by the Novel Histone Deacetylase Inhibitor AR-42()()
por: Henderson, Sally E., et al.
Publicado: (2016)

Pancreatic Adenocarcinoma Therapeutic Targets Revealed by Tumor-Stroma Cross-Talk Analyses in Patient-Derived Xenografts
por: Nicolle, Rémy, et al.
Publicado: (2017)

The prognostic role of desmoplastic stroma in pancreatic ductal adenocarcinoma
por: Wang, Lai Mun, et al.
Publicado: (2015)

Expression and role of the immune checkpoint regulator PD-L1 in the tumor-stroma interplay of pancreatic ductal adenocarcinoma
por: Daunke, Tina, et al.
Publicado: (2023)

Anti-IL-6 and PD-L1 antibody combination therapy reduces tumor progression in murine models of pancreatic cancer
por: Mace, Thomas, et al.
Publicado: (2015)

The role of microbiome in pancreatic cancer
por: Li, Jenny Jing, et al.
Publicado: (2021)

Novel agents for pancreatic ductal adenocarcinoma: emerging therapeutics and future directions
por: Zhang, Yiyin, et al.
Publicado: (2018)

Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma
por: Moffitt, Richard A., et al.
Publicado: (2015)

Complete clinical response of metastatic hepatocellular carcinoma to sorafenib in a patient with hemochromatosis: A case report
por: So, Brian J, et al.
Publicado: (2008)

Targeting the Stroma in the Management of Pancreatic Cancer
por: Edwards, Penelope, et al.
Publicado: (2021)

Targeting the tumor stroma for cancer therapy
por: Xu, Maosen, et al.
Publicado: (2022)

Is hyaluronan deposition in the stroma of pancreatic ductal adenocarcinoma of prognostic significance?
por: Gebauer, Florian, et al.
Publicado: (2017)

The Desmoplastic Stroma Plays an Essential Role in the Accumulation and Modulation of Infiltrated Immune Cells in Pancreatic Adenocarcinoma
por: Tjomsland, Vegard, et al.
Publicado: (2011)

Pancreatic cancer stem cells may define tumor stroma characteristics and recurrence patterns in pancreatic ductal adenocarcinoma
por: Askan, Gokce, et al.
Publicado: (2021)

A novel mutation in the tyrosine kinase domain of ERBB2 in hepatocellular carcinoma
por: Bekaii-Saab, Tanios, et al.
Publicado: (2006)

Immunological predictors of overall survival in treatment naïve metastatic pancreatic cancer patients
por: Farren, Matthew R, et al.
Publicado: (2015)

BMS-911543 inhibits viability of tumor and stromal cells and limits disease progression in genetically engineered mice with pancreatic cancer
por: Mace, Thomas, et al.
Publicado: (2014)

Tumor Stroma Area and Other Prognostic Factors in Pancreatic Ductal Adenocarcinoma Patients Submitted to Surgery
por: Amaral, Maria João, et al.
Publicado: (2023)

Real-World Dosing Patterns and Outcomes of Patients With Metastatic Pancreatic Cancer Treated With a Liposomal Irinotecan Regimen in the United States
por: Barzi, Afsaneh, et al.
Publicado: (2020)

Nomogram for Predicting Survival in Patients Treated with Liposomal Irinotecan Plus Fluorouracil and Leucovorin in Metastatic Pancreatic Cancer
por: Chen, Li-Tzong, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_m9f8tqcrtmdqg9k8m9ovmmbf6s